ArticleThe British journal of radiology2026
A novel prognostic model integrating the skeletal muscle index and systemic immune-inflammation index improves outcome prediction in unresectable esophageal squamous cell carcinoma.
Article in The British journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesThis investigation sought to assess whether integrating the Skeletal Muscle Index (SMI) and Systemic Immune-Inflammation Index (SII) could enhance prognostic stratification and improve survival prediction in patients with advanced, unresectable esophageal squamous cell carcinoma (ESCC).
methodsThe study included 200 individuals with confirmed unresectable ESCC, all of whom received chemoradiotherapy either as monotherapy or combined with immunotherapy. Kaplan-Meier methods were used to generate overall survival (OS) and progression-free survival (PFS) curves, with survival differences between groups evaluated by the log-rank test. The prognostic value of the novel predictive scoring system, combining SMI and SII (SSG score), was analyzed using Cox proportional hazards regression models.
resultsIn the overall cohort, the median OS and PFS were 18 months and 11 months, respectively. The prognostic significance of the SSG score was confirmed by receiver operating characteristic (ROC) curve analysis, which yielded an area under the curve (AUC) of 0.690 (P < .05), reflecting strong discriminative power for patient prognosis stratification. Multivariate Cox regression identified the SSG score as an independent prognostic factor for both OS (HR 2.955, 95% CI: 1.351-6.465, P = .007) and PFS (HR 2.028, 95% CI: 1.187-3.463, P = .010) in unresectable ESCC patients.
conclusionsWe developed and validated the SSG scoring system, integrating SMI and systemic SII, for prognostic assessment in unresectable ESCC. The SSG score demonstrated independent prognostic value for both OS and PFS. These findings support its clinical applicability in risk stratification and individualized treatment decision-making. ADVANCES IN KNOWLEDGE: The SSG score holds promise for improving treatment decisions and prognosis management in patients with unresectable ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.